Therapeutics News and Research

RSS

Researcher isolates gene thought to play role in development of Alzheimer's disease

A team of international scientists, including a researcher from Simon Fraser University, has isolated a gene thought to play a causal role in the development of Alzheimer's disease. The Proceedings of the National Academy of Sciences recently published the team's study.

26 Feb 2014

Opiate use alters activity of specific protein needed for normal functioning of brain's reward center

Identifying the specific pathways that promote opioid addiction, pain relief, and tolerance are crucial for developing more effective and less dangerous analgesics, as well as developing new treatments for addiction.

25 Feb 2014

IRSF announces new research grants for translational research program and clinical trials

The International Rett Syndrome Foundation (IRSF) announces today ten (10) new research grants at leading global research institutions; a new Translational Research Program; and additional funding for current human clinical trials.

24 Feb 2014

Self Regional Healthcare, Clemson University expand partnership to accelerate rate of innovation in genetic medicine

A new partnership will establish formal collaboration among genetic researchers and Clemson University faculty at the Greenwood Genetic Center and Self Regional Healthcare, expanding an already successful working relationship.

24 Feb 2014

Policy statement suggests ways to improve drug safety and efficacy in children

With less than half of medications including specific labeling for children, Kathleen Neville, MD, MS, a physician at Children's Mercy Hospital, recently led an American Academy of Pediatrics (AAP) committee in updating the policy with new recommendations guiding the off-label use of drugs in pediatric patients.

24 Feb 2014

IIN collaborates with Nanyang Technological University to establish Nanomedicine

Northwestern University's International Institute for Nanotechnology (IIN) is collaborating with Nanyang Technological University (NTU), Singapore, to establish the NTU-Northwestern Institute for Nanomedicine.

24 Feb 2014

Cell therapy: A powerful treatment for cancer patients

Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.

24 Feb 2014

New innovative technique can carry chemotherapy safely and release inside cancer cells

Researchers from the cancer nanotechnology and signal transduction and therapeutics programs of UCLA's Jonsson Comprehensive Cancer Center (JCCC) have developed an innovative technique that can carry chemotherapy safely and release it inside cancer cells when triggered by two-photon laser in the infrared red wave length.

24 Feb 2014

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD") and has collected the final data for evaluation of the primary endpoint.

23 Feb 2014

Chewable drug candidate BTI320 can potentially prevent added sugar intake

It's official: sugar is not so sweet—for our health, that is. The new study "Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults," published in JAMA Internal Medicine, examines the intake of "added sugars," and the results suggest that sugar is now an independent risk factor for heart disease and other chronic diseases.

21 Feb 2014

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.

21 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.

18 Feb 2014

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

Novartis acquires CoStim Pharmaceuticals

MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

17 Feb 2014

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases has awarded Soligenix a Small Business Innovation Research grant to support further preclinical development of SGX943 as a treatment for melioidosis.

14 Feb 2014

NIST scientists receives ABC Best Paper Award 2013 from Springer

The Springer journal Analytical and Bioanalytical Chemistry (ABC) has chosen Sherrie Elzey (32) and De-Hao Tsai (37) as the recipients of its Best Paper Award 2013.

14 Feb 2014

Researchers reveal how genome-editing tool works as 'guided missile' to correct errors in genetic code

Researchers from the Broad Institute and MIT have teamed up with colleagues from the University of Tokyo to form the first high definition picture of the Cas9 complex - a key part of the CRISPR-Cas system used by scientists as a genome-editing tool to silence genes and probe the biology of cells. Their findings, which are reported this week in Cell, are expected to help researchers refine and further engineer the tool to accelerate genomic research and bring the technology closer to use in the treatment of human genetic disease.

13 Feb 2014

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.

13 Feb 2014

Therapeutics News and Research

Researcher isolates gene thought to play role in development of Alzheimer's disease

Opiate use alters activity of specific protein needed for normal functioning of brain's reward center

IRSF announces new research grants for translational research program and clinical trials

Self Regional Healthcare, Clemson University expand partnership to accelerate rate of innovation in genetic medicine

Policy statement suggests ways to improve drug safety and efficacy in children

IIN collaborates with Nanyang Technological University to establish Nanomedicine

Cell therapy: A powerful treatment for cancer patients

New innovative technique can carry chemotherapy safely and release inside cancer cells

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

Chewable drug candidate BTI320 can potentially prevent added sugar intake

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Novartis acquires CoStim Pharmaceuticals

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

NIST scientists receives ABC Best Paper Award 2013 from Springer

Researchers reveal how genome-editing tool works as 'guided missile' to correct errors in genetic code

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News